Optimisation of a primary human CAR-NK cell manufacturing pipeline.
Aline PfefferleJulian ContetKahlia WongCharlotte ChenEls VerhoeyenChloe K SlichterKimberly S SchlunsJoseph CursonsRichard BerryIva NikolicJai RautelaNicholas D HuntingtonPublished in: Clinical & translational immunology (2024)
Our optimised manufacturing pipeline dramatically improves lentiviral transduction efficiency of primary human NK cells. We conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make peripheral blood-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.